Horizon's Genmab drug gets blockbuster status
After the first nine months of 2021, sales of Tepezza have crossed the important USD 1bn annual sales threshold.
by elizabeth mønsted johansen, translated by catherine brett
Horizon therapeutics has sold more than twice as much of its drug Tepezza during the first nine months of 2021 than it did during the same period last year, its Q3 report reveals.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab sales of Darzalex exceed expectations in Q3
For subscribers
New Genmab/Seagen drug will cost up to USD 120,000
For subscribers
